Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Sep 2013
Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.
There is a medical need for diagnostic biomarkers in lung cancer. We evaluated the diagnostic performance of complement activation fragments. ⋯ Complement fragment C4d may serve as a biomarker for early diagnosis and prognosis of lung cancer.
-
J. Natl. Cancer Inst. · Sep 2013
Multicenter StudyCost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
To reduce mortality, women with a family history of breast cancer are often screened with mammography before age 50 years. Additional magnetic resonance imaging (MRI) improves sensitivity and is cost-effective for BRCA1/2 mutation carriers. However, for women with a family history without a proven mutation, cost-effectiveness is unclear. ⋯ Screening with MRI may improve survival for women with familial risk for breast cancer but is expensive, especially in the youngest age categories.